Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

487
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
487
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

416
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
416
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

131
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
131
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

454
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
454

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single Interventions (Pharmacological or Renal Denervation) Are Not Sufficient to Achieve Blood Pressure Control in Resistant Hypertension: A Systematic Review and Meta-Analysis.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED.

Journal of the American Heart Association·2026
Same author

Artificial Intelligence in Biomedical Scientific Publishing.

European heart journal·2026
Same author

Bridging the gap: adapting heart failure guidelines for resource-limited settings: A European Journal of Heart Failure expert consensus document.

European journal of heart failure·2026
Same author

DIGIT-HF: Results From the Win Ratio Analyses.

Circulation. Heart failure·2026
Same author

Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms.

Nature communications·2026

Related Experiment Video

Updated: Aug 24, 2025

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.5K

Optimization of Heart Failure Treatment by Heart Rate Reduction.

Michael Böhm1, Yvonne Bewarder1, Ingrid Kindermann1

  • 1Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Germany.

International Journal of Heart Failure
|October 20, 2022
PubMed
Summary

Optimizing heart rate with ivabradine in heart failure (HF) patients can reduce cardiovascular death and hospitalizations. Achieving a heart rate of 50-60 bpm is associated with the lowest event rates, making heart rate a treatable risk factor.

Keywords:
Cardiovascular comorbiditiesChronic heart failureHeart rateHeart rhythmIvabradinePatient outcomes

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Related Experiment Videos

Last Updated: Aug 24, 2025

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.5K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) management requires optimizing heart rate beyond standard therapies.
  • Elevated heart rate in HF patients is linked to increased cardiovascular events.

Purpose of the Study:

  • To evaluate the efficacy of ivabradine in reducing cardiovascular death and HF hospitalizations.
  • To determine the optimal heart rate target for patients with chronic HF.

Main Methods:

  • Utilized ivabradine to achieve a target heart rate of 50-60 bpm in patients with heart rate >70 bpm, sinus rhythm, and ejection fraction ≤35%.
  • Analyzed event rates based on baseline resting heart rate and achieved heart rate reduction.

Main Results:

  • Heart rate reduction significantly decreased cardiovascular death and HF hospitalizations, particularly in patients with baseline heart rate >75 bpm.
  • The lowest event rates were observed when a well-tolerated heart rate between 50-60 bpm was achieved.
  • Heart rate reduction was identified as a treatable risk factor in chronic HF.

Conclusions:

  • Ivabradine is effective in optimizing heart rate for patients with chronic HF, reducing adverse cardiovascular outcomes.
  • Targeting a heart rate of 50-60 bpm is beneficial for managing chronic HF.
  • Further research is warranted to explore heart rate reduction's role in other cardiovascular and non-cardiovascular conditions.